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Abstract
Background: In the last few decades, the number of trials using Bayesian methods has grown rapidly. Publications
prior to 1990 included only three clinical trials that used Bayesian methods, but that number quickly jumped to 19
in the 1990s and to 99 from 2000 to 2012. While this literature provides many examples of Bayesian Adaptive
Designs (BAD), none of the papers that are available walks the reader through the detailed process of conducting a
BAD. This paper fills that gap by describing the BAD process used for one comparative effectiveness trial (Patient
Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations) that can be generalized for use
by others. A BAD was chosen with efficiency in mind. Response-adaptive randomization allows the potential
for substantially smaller sample sizes, and can provide faster conclusions about which treatment or treatments
are most effective. An Internet-based electronic data capture tool, which features a randomization module,
facilitated data capture across study sites and an in-house computation software program was developed to
implement the response-adaptive randomization.
Results: A process for adapting randomization with minimal interruption to study sites was developed. A new
randomization table can be generated quickly and can be seamlessly integrated in the data capture tool with
minimal interruption to study sites.
Conclusion: This manuscript is the first to detail the technical process used to evaluate a multisite comparative
effectiveness trial using adaptive randomization. An important opportunity for the application of Bayesian trials is in
comparative effectiveness trials. The specific case study presented in this paper can be used as a model for conducting
future clinical trials using a combination of statistical software and a web-based application.
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Background
Challenging statistical issues often arise when designing,
analyzing, and conducting clinical trials that assess safety
and effectiveness of treatments [1]. Bayesian methodology
offers much to address these challenges. It is well-suited
for flexible adaptation and can lead to more efficient trials
with more patients receiving better treatment [2]. With
recent advances in technologies and the availability of
prior information, Bayesian Adaptive Designs (BAD) are
ready for broader applications [3]. Indeed, the number of
trials using Bayesian methods has grown rapidly over
time. Prior to 1990 only three published clinical trials
used Bayesian methods, but that number quickly
jumped to 19 in the 1990s and to 99 from 2000 to 2012
[4]. Reflecting this increased interest in using Bayesian
methodology, the Patient Centered Outcomes Research
Institute (PCORI), a leading funder of comparative ef-
fectiveness research in the USA, has adopted specific
policies and guidelines encouraging the use of BAD in
comparative effectiveness trials [5].
Published reports of studies using BAD, however,
generally report on the design and results found, but
provide little information on the process of adaptation
used that would allow others to replicate the study, a
key feature for advancing science and confirming evi-
dence for translation into clinical practice. Lee and Chu
conducted an extensive literature review to ascertain
how Bayesian methods have been applied in the design,
implementation, and analysis of real clinical trials. They
found that while most trials (62 %) applied Bayesian
methods for testing treatment efficacy, only about 5 %
looked at both efficacy and safety, approximately 5 %
applied adaptive randomization, and an even smaller
percentage had more than three treatment groups [4].
Although literature is available detailing the Bayesian
methods that have been applied in the design and ana-
lysis of real clinical trials, there are very few reports on
the implementation of Bayesian methods. The literature
does not provide detailed information on how the stud-
ies were actually conducted, i.e., the computational
approaches to the adaptation processes.
Tools needed to conduct BAD
Bayesian trials depend on timely data entry for outcomes
to inform the adaptation rules in real time [4] and this
has presented additional challenges for investigators.
While general computing tools have been developed in
recent years to assist with some of the inherent compu-
tational demands of adaptation, specialized computer
programs remain necessary to design and conduct a
Bayesian study and to allow for replication by providing
information on how the adaptation process was applied.
In our review of published papers of BAD studies, it was
nearly impossible to determine how the adaptive
randomization was conducted. A multicenter breast
cancer study (I-SPY 1) that integrated clinical, imaging,
and genomic data to evaluate pathologic response, as
well as their relationship and predictability based on
tumor biomarkers, mentioned developing a web-based
system called caINTEGRATOR as a common platform
for data acquisition [6]. While the article provided a
link to learn more about caINTEGRATOR, the web-
page provided few details about the process or imple-
mentation of the adaptive randomization used. A
clinical trial conduct (CTC) platform also was devel-
oped at the University of Texas MD Anderson Cancer
Center to facilitate conducting Bayesian clinical trials
[4]. Details about the functionality of the CTC platform
used in the Biomarker-integrated Approaches of Tar-
geted Therapy for Lung Cancer Elimination (BATTLE)
trial, however, were limited to describing that after the
patient’s eligibility criteria are entered by a nurse coord-
inator, the information is passed to an R script through
web services, which performs Bayesian computations to
determine the randomization probability and randomizes
patients to eligible treatments accordingly [4]. Similarly,
a Bayesian adaptive design for lung cancer therapy [7]
provided few details.
An adaptive trial requires a system to manage random
assignment to treatment arms. When the trial is multi-
site, a centralized randomization table is needed for use
across all sites. With Bayesian methods, randomization
is adapted at each interim analysis and it is, therefore,
necessary to ensure that all sites begin using the up-
dated allocation table at the same time [8] to uniformly
support data acquisition. Integrating electronic data
systems/capture and computational software clearly fa-
cilitates implementing and adopting Bayesian methods
in clinical trials. For multisite studies, web-based appli-
cations are especially valuable primary tools to capture
the data and provide for timely data entry and analysis.
Web-based services also provide additional benefits
such as exchanging information between the database
module and the computing module [4].
This manuscript is the first to detail the technical
process used to evaluate a multisite comparative ef-
fectiveness trial using adaptive randomization. An im-
portant opportunity for the application of Bayesian
trials is in comparative effectiveness trials. The spe-
cific case study presented in this paper can be used
as a model for conducting future clinical trials using
a combination of statistical software and a web-based
application. In this paper we describe how computa-
tional software programs were used for conducting a
Bayesian adaptive clinical trial. The programs are used
for generating new randomization tables that can be
integrated in data capture tools in one comparative
effectiveness trial.
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Methods
Our illustrative trial, Patient Assisted Intervention for
Neuropathy: Comparison of Treatment in Real Life
Situations (PAIN-CONTRoLS) is a multisite Bayesian
prospective adaptive randomization trial with four arms
that combines safety and efficacy. This ambitious trial
was sorely needed, but it presented many logistical chal-
lenges. Because there have been no previous trials of
drugs to treat pain in patients with cryptogenic sensory
polyneuropathy (CSPN) [9], there not only has been
no information to guide physicians treating CSPN pa-
tients, but insurance carriers often reject authorizing
prescriptions for some drugs commonly used for
other neuropathies. Therefore, we proposed conduct-
ing this comparative effectiveness prospective study
using drugs commonly prescribed by physicians when
caring for CSPN patients.
For illustrative purposes some brief additional infor-
mation about our study is presented here. Cryptogenic
sensory polyneuropathy (CSPN), also known as idio-
pathic polyneuropathy, is the diagnosis assigned when
known causes of neuropathy have been excluded [9].
Seventy to eighty percent of CSPN patients present with
pain ([9] and [10]). The trial goal is to identify which
drug is most effective in reducing pain with the fewest
side effects. Pain [11] at 12 weeks after study enrollment
is the primary end point for our study. Study partici-
pants are randomized to one of four drugs and pain was
measured at 4 and 8 weeks, in addition to our 12-week
primary end point. Each participant is rated at each
measurement time as either staying on the drug or quit-
ting the drug due to lack of efficacy or adverse side
effects (i.e., “quit” is not good). If the patient was able to
remain on the drug, it was determined whether the drug
was considered efficacious or not. Efficacy is defined as a
50 % or more reduction in the Likert pain scale from
baseline to the follow-up visit. We estimated a need for
40 sites, with each site enrolling an average of 10 pa-
tients for a total sample size of 400. All of the sites are
located in the USA except one located in Canada. We
will be utilizing response-adaptive randomization based
on the 4-, 8-, and 12-week patient outcomes. The adap-
tations are to occur after 80 patients have been enrolled
and then every 13 weeks after that. For this study, a
central Institutional Review Board (IRB) of record is
the Human Subjects Committee and the ethics com-
mittee is the Human Research Protection Program,
both at University of Kansas Medical Center. The IRB
# is STUDY00001500. The study was first approved
by the IRB on 24 September 2014.
Bayesian Adaptive Design
The BAD for this study is driven entirely by the 12-week
response (quit or not; and if still on the drug, efficacious
or not). We label the response for patient i at weeks 4,
8, and 12 as vectors of length three, Yi,4, Yi,8, and Yi,12,
respectively, with each component of the three-
dimensional vector representing the follow-up response
for that patient. The sample size and the randomization
ratio to each arm depend on the accumulating informa-
tion in the trial.
First there is an initial Burn-in phase. For our study
this was defined as equally randomizing 80 participants
to the four arms (20 per arm.) Each participant must
complete and sign a study consent form and upon
randomization to the treatment drug, must then sign a
second, drug-specific consent form. If the patient refuses
to sign either, they will not be considered enrolled in the
study. After the 80th participant is enrolled, any longitu-
dinal data that is collected up to that point will be used
to drive the first adaptive randomization. The Adaptive
randomization phase, where adaptations occur every 13
weeks, comes after the Burn-in phase. In this phase, a
vector of probabilities, q = (q1, q2, q3, q4), is created from
an analysis of the current longitudinal data. From this
point forward patients are allocated according to this,
and subsequent, response-adaptive randomization vec-
tors. At each update during the Adaptive randomization
phase a decision is made on whether or not a best drug
has been identified (i.e., the posterior probability of the
most effective drug is at least 0.925.) If so, and if this
occurs before enrolling all patients initially planned for,
the trial is stopped for early success. The trial will be
considered a success if either of the following occurs:
1. Early success: if at any interim analysis the most
likely arm has at least a 0.925 posterior probability
of being the best arm
2. End-of-trial success: if at the conclusion of
participation by 400 patients, the most likely arm
has at least a 0.925 posterior probability of being
the best arm
While there may not be a single clear best arm, any
arm with a posterior probability of no more than 0.01
will be designated a “loser” and no more patients will be
randomized to that arm. This value was selected based
on data from simulations that suggested a higher poster-
ior probability value would lead to an unacceptable
“loser” false discovery rate.
The study team investigated several operating charac-
teristics including power, trial size, patient allocation
across arms, and trial duration. From these simulations,
it was learned that the trial has a Type I error rate of ap-
proximately 5 %. In the likely scenario of one best arm,
the trial has 94 % power with an average sample size of
266, well below the 400, with over half of those patients
receiving the best treatment. The design for this trial
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also allows for the declaration of loser arms if no true
winner is present.
End point and longitudinal statistical modeling
The response for patient i, at the 12-week visit is a
three-dimensional vector Yi,12. The model has a multi-
nomial distribution Yi,12 which approximates to Multi-
nomial(θai), where ai is the treatment arm for patient i.
The response to pain medication (rates of quit and
efficacy) at 12 weeks for arm a is a three-dimensional
vector θa (quit; not quit and efficacious; not quit and not
efficacious.) Uniform priors are provided (θa) approxi-
mating to Dirichlet (1/3,1/3,1/3) [12]. To measure the
utility of an arm the components of θa are combined to
obtain a utility, Ua, for the a
th drug. The formula is:
Ua ¼ 0:75θa;2 þ 1−θa;1
 
;
where θa,1 and θa,2 represent the quit rate and efficacy
rate respectively for drug a.
This utility function was chosen after discussion with
clinical experts regarding the relative utility of quit and
efficacy, a process described in Gajewski et al. [12].
At each interim analysis some patients will have
complete information on their 12-week observation,
Yi,12. These patients may also have their interim values
of response to pain medication observed, Yi,4 and Yi,8.
There also will be patients with interim responses,
but no 12-week value, and patients with no responses.
We use information from patients with incomplete
information to the extent that the interim values from
those with complete data are predictive of the final
12-week values.
A conditional multinomial model is created for the
prediction between each interim time period response
value and the 12-week values. A separate version of
the model is used for each experimental arm and
each time period. The multinomial model is used only
on patients who stay on medication, as anytime a pa-
tient quits a medication subsequent observations are
also “quit”’ The priors used for these models are as
follows: we let p21, p22, and p23, the 12-week prob-
abilities of quit, not quit efficacy, and not quit no ef-
ficacy, be conditional on a patient showing early
efficacy at 4 or 8 weeks. For these we use a Dirichlet
prior, (p21, p22, p23) which approximates to Dirichlet
(1, 7, 2), representing a priori mean rates of 10 %, 70
%, and 20 % at 12 weeks for early efficacy. These
priors were elicited from clinical experts. For a pa-
tient who shows no efficacy early, the final prior
probabilities are (p31, p32, p33) which approximates
to Dirichlet (1, 2, 7), representing a priori mean rates
of 10 %, 20 %, and 70 % at 12 weeks for patients
showing early no efficacy. These are fairly “weakly
informative,” each having a prior sample size equiva-
lent to 10 patients.
Bayesian quantities
The following Bayesian quantities, calculated at each in-
terim analysis, are used in the adaptive design. The pos-
terior probability that each arm, a = 1,2,3,4, is the
maximally effective arm, Pa
max, is calculated from the
joint posterior distribution. The arm with the largest
Pa
max is labeled the most likely maximum effective drug,
as determined by the posterior utility function (i.e., Pa
max
is a function of Ua). The posterior mean and variance
for each utility also is calculated. We label V(Ua) as the
posterior variance of the parameter Ua.
Adaptive randomization
As previously identified, during the initial Burn-in phase
(with 80 patients in our trial) allocation is set at 1:1:1:1
for arms 1, 2, 3, and 4, respectively. After the Burn-in
phase, adaptive allocation randomization is used in
which the allocation probabilities are updated quarterly
to favor those drugs most likely to be the best. After
exploring the operating characteristics for monthly, bi-
monthly, and quarterly adaptations, quarterly adapta-
tions were decided upon for a couple reasons. The
operating characteristics did not significantly diminish
when performing quarterly adaptations, but the time
and resource burden for the study team were drastically
reduced. The randomization vector of probabilities is
created by selecting a vector based on the posterior
distribution of the utility function for each arm.
The posterior variance of Ua for each drug, and the
posterior probability that each drug is the best arm, is
used for the specification of the randomization vector.
Let the number of patients enrolled in arm a be na. The
goal of adaptive randomization is to allocate more
patients to the arms most likely to be the best, as well as
to learn about which arm is best. A variance component,
Va, as well as the probability drug a is the maximally
effective arm, Pa
max, are, therefore, constructed for each
arm. The information for arms a = 1,2,3,4 is:
Ia ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
Pmaxa V Uað Þ= na þ 1ð Þ
q
:
The randomization probabilities for each of these
drugs will be proportional to Ia. The randomization vec-
tor, q, is set as qa = Ia/∑Ia. The information measure was
chosen because it randomizes more patients to the arm
with higher standard error if all posterior probabilities
that the arm is the best are the same. Sole allocation
based on probability does not have this property.
Three example interim analyses are shown in Fig. 1. In
the first interim analysis a new adaptive randomization
is calculated after the initial equal allocation to each
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group. Some of the patients have no data while others
have 4-, 8-, or 12-week data. The adaptive randomization
uses all patient data with at least 4 weeks of data. As
seen in Fig. 1, the first test interim analysis shows
Treatment 3 trending toward the “best” but not quite at
the predefined success criterion. The second interim
analysis shown has many more mock patients and, con-
sistent with the adaptive randomization approach, more
are randomized to Treatment 3 but the study has not
been stopped for success. The third interim analysis
shown indicates “success,” and Treatment 3 is deemed
the best. Note that the bottom-most histogram reflects
that no patients were enrolled in Treatments 1 and 4
after the second interim analysis because the posterior
probabilities for those arms were 0.01 or less and, thus,
they were deemed “losers.”
Trial computational tools (REDCap™, SAS®, R)
For our study we developed an in-house computation soft-
ware program built in REDCap™ [13], SAS® [14], and R
[15]. This platform provides a smooth transition between
randomization sequences at each adaptation during the
trial (Fig. 2), without interference to any of the multiple
sites. REDCap (http://project-redcap.org/) [13] is a popular
web application used for capturing research study data, and
while a basic randomization module exists within REDCap,
a more novel model was required for our longitudinal, mul-
tisite BAD. SAS® and R were used to clean the data, per-
form the analyses, and generate the new allocation ratios
and randomization table. Our enhancements work in con-
junction with REDCap to accomplish response-adaptive
randomization. Our design is just one example, but we be-
lieve that researchers using BADs would benefit from
adopting, and modifying if needed, the web-based central-
ized system we developed and present here.
Some logistical challenges arise in multisite trials
when the randomization table needs to be updated at
every interim analysis. Our trial is conducted at 40
sites across the country and each site began, or will
begin, enrollment at different times. It was decided
that an Internet-based randomization process would
be most effective— especially since clinicians needed
to provide the patient with a prescription for their
treatment drug at the patient’s clinic visit. An
Fig. 1 An example of first, second, and third interim analysis
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Internet-based randomization process also enables all
sites to use one master allocation table and ensures
that only one allocation table needs updating by the
statistician at each response-adaptive randomization.
Another goal was to ensure that none of the sites
would be affected by any lag in the study process
when an adaptation in the randomization sequence
occurred, and having one master Internet-based allo-
cation table has allowed us to achieve that goal.
Using one electronic data capture tool database, RED-
Cap [13], across all sites also helped to reduce some of the
logistical challenges. It was determined that utilizing one
stand along system, such as REDCap, that allows the re-
searchers across all the sites to collect the data in a timely
manner and would allow real-time randomization, was
most efficient and effective for this trial. The lead investi-
gator’s institution, the University of Kansas Medical Cen-
ter, hosts the data warehouse and portal for data
collection, storage, and management from all sites. The
REDCap tool contains eight forms to capture all data
needed. Within REDCap, each site is assigned its own data
access group to ensure that team members from each site
had access to only the patients from their site.
Conducting a BAD trial using REDCap
More than 157,000 projects created by more than
216,000 users from nearly 1400 institutions in 88
countries have used REDCap and published over 1365
articles since 2008 [16]. Of these, just over 60 studies are
randomized trials, and only one article reported using a
BAD [16]. Not surprisingly, details about how adaptive
randomization was implemented in the REDCap system
were not reported. By describing how the adaptive
randomization was implemented for our study using this
widely available program, we hope to begin to address
this gap in the literature.
The front end of the REDCap application is built on a
server-side scripting language designed for web develop-
ment (PHP) and the backend of the application resides
on a MySQL database. REDCap has a default built-in
module for randomization. The allocation table for our
BAD trial is a random combination of four different
numbers (i.e., 1, 2, 3, and 4), each corresponding to a
different study drug. It should be noted that although
this trial chose not to stratify the randomization by site,
due to a small expected number of patients to be en-
rolled across all the sites, the REDCap application has
the capabilities to include a stratification variable in the
randomization table. This would function well for trad-
itional, stratified randomization trials and for stratified
response-adaptive randomization trials.
The initial allocation table is uploaded and attached to
the study through the built-in module within REDCap.
Once basic demographics have been entered for a
Fig. 2 Overall schematic of the trial’s conduction
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patient, a banner is displayed to the research site coord-
inator indicating whether or not the patient is eligible
for the study. If eligible, the site coordinator clicks the
randomization button on the study form and the next
available slot on the allocation table is assigned to that
patient Fig. 3. Twenty extra slots were added to the allo-
cation table in case the 81st patient needed to be ran-
domized while we prepared the next adapted allocation
table. Once we assign 80 of these 100 slots, the data
from REDCap is extracted and analyzed in SAS and then
R is used to generate the new allocation table. Any
remaining unassigned slots in the first randomization
table are deleted and the new table is appended to
the existing table. This process is repeated every 13
weeks using available data to repeat the adaptive
randomization process.
Another trial tool – eResearch
Another option available to investigators is eResearch, a
secure, web-based clinical trial management tool that
can be used to maintain all the study information and
research patient information [17]. The front end of eRe-
search is built on Java server pages (JSP) and the back-
end (i.e., the database) resides on Oracle 11G. This
application includes all the same features available in
REDCap, including the capability of performing fixed
or adaptive randomization. The only difference is that
eResearch focuses more on clinical usage, as it is pri-
marily a clinical trial management tool, while REDCap
is strictly a data capture tool. Based upon study prefer-
ences and priorities, investigators may use whichever
tool best suits their needs.
Another major challenge that comes with using an
electronic data capture system is the possibility that a
computer, or Internet access, may not be available in the
clinic during the patient’s visit. While a reliable paper
backup of the study forms for data capture is available
for such an event at each site, research staff at the lead
investigator’s institution must be available (by phone) in
case the randomization module would also be unavail-
able. This ensures that the clinician would still have the
ability to randomize the patient during the clinic visit
and provide a prescription at that time.
Results
As each adaptation in the allocation table approaches we
are ensuring that the follow-up data for the study pa-
tients is being entered into the electronic database in a
timely matter. Most sites are performing direct data
entry and sites are being queried if a patient’s follow-up
visit data is not in at the scheduled visit time. Data
cleaning is also being performed every few weeks to
Fig. 3 Screen shots from the randomization procedure within REDCap
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verify the data quality. Any discrepancies or missing data
values are being directed to the corresponding site co-
ordinator for correction or clarification. The site coordi-
nators will be correcting any patient data directly in the
REDCap database. This ensures that the next time the
data is extracted it will be correct and as up-to-date as
possible. REDCap has an excellent logging tool that al-
lows us to keep track of any changes that were made to
the data, the user who made the changes, and when
those changes were made. We wanted to ensure that all
of the data was error free and complete as we approach
the end of each portion of enrollment. For the adap-
tation, it is important for us to be able to use all of
the longitudinal patient data that has been collected
to inform our new allocation table. Larger studies
may want to consider utilizing automated email mes-
sages to clinical staff to remind them of the patient’s
follow-up schedule.
Prior to the first adaptation, we were working on de-
veloping an automated process, which would enable us
to: (1) extract the data, (2) run the data cleaning process,
(3) determine if a patient was categorized as quit, not
quit and efficacious, or not quit and not efficacious for
each visit, (4) generate the new randomization sequence
needed for the next cohort of patients; and (5) append
that new sequence to the existing allocation table seam-
lessly, without disturbance to any of the sites that were
currently enrolling patients. The 80th patient was ran-
domized to a study drug on 3 December 2015. The data
was extracted from REDCap that evening. The extracted
data was cleaned, and analyzed using SAS 9.4. For each
time point the patients had completed, we determined if
they were categorized as quit, not quit and efficacious,
or not quit and not efficacious for each visit. A file was
created from SAS containing the longitudinal data for
each patient. The longitudinal model algorithm was pro-
grammed in R. The R program used the file that was
created in SAS to calculate the posterior probabilities of
the treatment arms (interim analysis) and to generate
the new allocation table using the SAMPLE function in
R. The new table was then appended to the existing
randomization table within REDCap on the afternoon of
4 December. In total, it took less than 24 hours from
when the 80th patient was randomized to upload and
have the new randomization table that utilized the new
allocation probabilities ready for the next patient. Finally,
after a site had randomized another patient, it was con-
firmed that the patient was randomized to the treatment
drug that was found in the first spot of the new
randomization table.
There are now 154 total patients enrolled on the study,
with 33 sites currently enrolling. We have performed an
additional response-adaptive randomization, which oc-
curred in March, and the same process was utilized from
the first adaption. It went very smoothly and we were able
to extract the data and append the new randomization
table with the updated allocation ratios to the REDCap
database within two business days.
Discussion
Due to this trial being completely unblinded, in general,
physician bias could be an issue. However, the physician
was left unblinded for two reasons. First, the sponsor’s
(PCORI) goal is to emulate real clinical practice (i.e.,
pragmatic) and wanted this to be unblinded. Second, the
physicians at each site are enrolling a small number
of patients and are enrolling very slowly. We did not
expect them to develop any bias to prescribing one of
the four treatment groups. It should be noted that
after each response-adaptive randomization, a Data
Safety Monitoring Board (DSMB), along with the en-
rolling physicians, receive a report that details the
adaptation. We have given the treatment drugs gen-
eric labels (A, B, C, D) so as to blind the DSMB and
enrolling physicians from which drugs are performing
better or worse than the others.
While we have pointed out many of the benefits
of response-adaptive randomization, there are some
drawbacks that should be mentioned. Meurer et al.
described some barriers to the adoption of adaptive
clinical trial design as “increased complexity during
both study design and trial conduct,” and “questions
about the receptiveness of funding agencies and peer
reviewers” [18]. Some of the complexity during trial
conduct, specifically the changes in randomization
ratios that need to be periodically implemented, has
become more available due to computerized central
randomization. The innovative process we describe in
our paper is a prime example of how we were able to
achieve this.
Conclusions
The Bayesian Adaptive Design (BAD) was chosen with
efficiency in mind. Using adaptive randomization not
only allows for substantially smaller sample sizes, but
also provides better conclusions about what treatments
are the most effective, because it lets us make changes
to our approach or stop the study early if we find strong
results before the scheduled end of the study. While the
study is still enrolling, the first adaptation in the
randomization provided drastic changes to the initial
1:1:1:1 allocation ratio.
REDCap is a popular tool used by many for randomized
clinical trials. As more Bayesian clinical trials are being
conducted in practice, additional information about how
this program can be used for BAD trials is needed. In this
paper we detailed how an adaptive randomization process
was developed for use with REDCap as an example for
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conducting a BAD comparative effectiveness trial where
data capture and randomization are accomplished in real
time. Our specific case study should serve as a model for
future clinical trials using a combination of statistical soft-
ware and web-based applications.
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